Search Results - "Reipert, B. M."

Dangerous liaisons: how the immune system deals with factor VIII by WROBLEWSKA, A., REIPERT, B. M., PRATT, K. P., VOORBERG, J.

“…Only a fraction of patients with hemophilia A develop a neutralizing antibody (inhibitor) response to therapeutic infusions of factor VIII. Our present…”
Get full text

Immunomodulatory properties of human serum immunoglobulin A: anti‐inflammatory and pro‐inflammatory activities in human monocytes and peripheral blood mononuclear cells by Olas, K., Butterweck, H., Teschner, W., Schwarz, H. P., Reipert, B.

“…Summary Our study investigated the immunomodulatory activities of human plasma‐derived serum immunoglobulin (Ig)A. Previous findings seem contradictory…”
Get full text

Comparative analysis of marketed factor VIII products: reply by Reipert, B. M., Anzengruber, J., Scheiflinger, F.

Get full text

In‐depth comparison of N‐glycosylation of human plasma‐derived factor VIII and different recombinant products: from structure to clinical implications by Canis, K., Anzengruber, J., Garenaux, E., Feichtinger, M., Benamara, K., Scheiflinger, F., Savoy, L.‐A., Reipert, B. M., Malisauskas, M.

“…Essentials Glycosylation heterogeneity of recombinant proteins affects pharmacokinetics and immunogenicity. N‐glycomics/glycoproteomics of plasma‐derived…”
Get full text

Suppression of apoptosis allows differentiation and development of a multipotent hemopoietic cell line in the absence of added growth factors by Fairbairn, L J, Cowling, G J, Reipert, B M, Dexter, T M

“…In the absence of growth factors, hemopoietic cells die rapidly by the process of apoptosis. Transfection of the human bcl-2 gene into an interleukin-3…”
Get more information

Increase in autoantibodies against fas (CD95) during carcinogenesis in the human colon : a hope for the immunoprevention of cancer? by REIPERT, B. M, TANNEBERGER, S, PANNETTA, A, BEDOSTI, M, POELL, M, ZIMMERMANN, K, STELLAMOR, M. T

“…A thorough understanding of the naturally occurring events in the immune system in response to carcinogenesis will facilitate the development of strategies for…”
Get full text

Comparative analysis of marketed factor VIII products: recombinant products are not alike vis‐a‐vis soluble protein aggregates and subvisible particles by Anzengruber, J., Lubich, C., Prenninger, T., Gringeri, A., Scheiflinger, F., Reipert, B. M., Malisauskas, M.

“…Essentials Aggregation is a critical quality attribute of protein therapeutics influencing immunogenicity. Aggregates and subvisible particles in 9 recombinant…”
Get full text

Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report by ASTERMARK, J., ALTISENT, C., BATOROVA, A., DINIZ, M. J., GRINGERI, A., HOLME, P. A., KARAFOULIDOU, A., LOPEZ-FERNÁNDEZ, M. F., REIPERT, B. M., ROCINO, A., SCHIAVONI, M., Von DEPKA, M., WINDYGA, J., FIJNVANDRAAT, K.

“…The development of inhibitors to the infused factor in patients with haemophilia is a serious clinical problem. Recent evidence suggests that alongside the…”
Get full text

Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance by Reipert, B M, Sasgary, M, Ahmad, R U, Auer, W, Turecek, P L, Schwarz, H P

“…Patients with severe hemophilia A frequently develop neutralizing anti-factor VIII antibodies after replacement therapy with factor VIII (FVIII). In a search…”
Get more information

Taking immunogenicity assessment of therapeutic proteins to the next level by Büttel, I.C., Chamberlain, P., Chowers, Y., Ehmann, F., Greinacher, A., Jefferis, R., Kramer, D., Kropshofer, H., Lloyd, P., Lubiniecki, A., Krause, R., Mire-Sluis, A., Platts-Mills, T., Ragheb, J.A., Reipert, B.M., Schellekens, H., Seitz, R., Stas, P., Subramanyam, M., Thorpe, R., Trouvin, J.-H., Weise, M., Windisch, J., Schneider, C.K.

“…Therapeutic proteins provide innovative and effective therapies for numerous diseases. However, some of these products are associated with unwanted…”
Get full text

The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development by Reipert, B.M., Gangadharan, B., Hofbauer, C.J., Berg, V., Schweiger, H., Bowen, J., Blatny, J., Fijnvandraat, K., Mullins, E.S., Klintman, J., Male, C., McGuinn, C., Meeks, S.L., Radulescu, V.C., Ragni, M.V., Recht, M., Shapiro, A.D., Staber, J.M., Yaish, H.M., Santagostino, E., Brown, D.L.

“…Preventing factor VIII (FVIII) inhibitors following replacement therapies with FVIII products in patients with hemophilia A remains an unmet medical need…”
Get full text

Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A by Reipert, B M, Ahmad, R U, Turecek, P L, Schwarz, H P

“…To investigate the usefulness of factor VIII (FVIII) knockout mice as an animal model of hemophilia A, we characterized the antibody response in FVIII knockout…”
Get more information

What can we learn from the immune response to human factor VIII in a mouse model of hemophilia A? by Reipert, B M, Schwarz, H P

Get more information

Opportunities and limitations of mouse models humanized for HLA class II antigens by REIPERT, B. M., STEINITZ, K. N., Van HELDEN, P. M., UNTERTHURNER, S., SCHUSTER, M., AHMAD, R. U., ILAS, J., SCHWARZ, H. P.

“…MHC class II molecules are essential for shaping the CD4+ T‐cell repertoire in the thymus and for selecting antigenic peptides that are presented to CD4+ T…”
Get full text

Modulation of factor VIII-specific memory B cells by REIPERT, B. M., ALLACHER, P., HAUSL, C., PORDES, A. G., AHMAD, R. U., LANG, I., ILAS, J., WINDYGA, J., KLUKOWSKA, A., MUCHITSCH, E. M., SCHWARZ, H. P.

“…The development of inhibitory antibodies against factor VIII (FVIII) is the major complication in patients with haemophilia A who are treated with FVIII…”
Get full text

Variation of anti-Fas antibodies in different lots of intravenous immunoglobulin by Reipert, B. M., Stellamor, M. T., Poell, M., Ilas, J., Sasgary, M., Reipert, S., Zimmermann, K., Ehrlich, H., Schwarz, H. P.

“…Background and Objectives  Previous studies have presented evidence that human immunoglobulin G preparations for intravenous use contain antibodies directed…”
Get full text

Natural Anti-Amyloid-beta Antibodies in Intravenous Immunoglobulin (IVIG) Preparation Attenuate Amyloid beta-Induced Neurotoxicity in vitro by Hermann, C, Schwarz, H.P, Ehrlich, H, Reipert, B.M, Olas, K

“…Preincubation of Aß42 with monoclonal anti-Aß42 antibodies decreased the Aß42 induced cytotoxicity in PC-12 cells. 6E10, a monoclonal antibody that shows…”
Get full text

Fc function of a new intravenous immunoglobulin product: IGIV 10% triple virally inactivated solution by Reipert, B. M., Ilas, J., Carnewal, C., üreder, S.F, Bölzlbauer, U., Teschner, W., Fiedler, C., Schwarz, H. P.

“…Background and Objectives  Baxter AG has developed a new liquid intravenous immunoglobulin product [Immune Globulin Intravenous (IGIV) 10%] using a new…”
Get full text

Apoptosis in haemopoietic progenitor cells exposed to extremely low-frequency magnetic fields by Reipert, Birgit M., Allan, Donald, Reipert, Siegfried, Dexter, T.Michael

“…Epidemiological studies have indicated a modestly increased risk for the development of acute myeloid leukaemia in children who live close to high-voltage…”
Get full text

Exposure to extremely low frequency magnetic fields has no effect on growth rate or clonogenic potential of multipotential haemopoietic progenitor cells by Reipert, B M, Allan, D, Dexter, T M

“…Recent reports indicate an increased risk of acute myeloid leukaemia in children exposed to extremely low frequency magnetic fields (ELFMFs) emitted by high…”
Get more information